Adverum Biotechnologies Inc (NASDAQ:ADVM) had its Hold rating reiterated by Chardan Capital with a $4.50 price target

Analyst Ratings For Adverum Biotechnologies Inc (NASDAQ:ADVM)

Story continues below

Today, Chardan Capital reiterated its Hold rating on Adverum Biotechnologies Inc (NASDAQ:ADVM) with a price target of $4.50.

There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Adverum Biotechnologies Inc (NASDAQ:ADVM) is Hold with a consensus target price of $8.8750 per share, a potential 172.67% upside.

Some recent analyst ratings include

  • 11/2/2018-Adverum Biotechnologies Inc (NASDAQ:ADVM) had its Hold rating reiterated by Chardan Capital with a $4.50 price target
  • 11/2/2018-Adverum Biotechnologies Inc (NASDAQ:ADVM) gets downgraded to Hold by SunTrust Banks
  • 11/2/2018-Adverum Biotechnologies Inc (NASDAQ:ADVM) gets downgraded to Market Perform by Raymond James


  • On 6/8/2015 Mehdi Gasmi, VP, sold 500 with an average share price of $38.64 per share and the total transaction amounting to $19,320.00.
  • On 6/8/2015 Paul Wachter, Director, sold 1,192 with an average share price of $38.64 per share and the total transaction amounting to $46,058.88.
  • On 5/26/2015 Paul Wachter, Director, sold 1,192 with an average share price of $36.94 per share and the total transaction amounting to $44,032.48.
  • On 5/22/2015 Steven Daniel Schwartz, Director, sold 16,875 with an average share price of $38.38 per share and the total transaction amounting to $647,662.50.
  • On 5/13/2015 Linda Bain, CFO, sold 285 with an average share price of $34.94 per share and the total transaction amounting to $9,957.90.
  • On 5/13/2015 Mark S Blumenkranz, Director, sold 715 with an average share price of $34.94 per share and the total transaction amounting to $24,982.10.
  • On 5/8/2015 Steven Daniel Schwartz, Director, sold 17,250 with an average share price of $33.05 per share and the total transaction amounting to $570,112.50.

About Adverum Biotechnologies Inc (NASDAQ:ADVM)
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Recent Trading Activity for Adverum Biotechnologies Inc (NASDAQ:ADVM)
Shares of Adverum Biotechnologies Inc closed the previous trading session at 3,24 −1,32 28,90 % with 3.36 shares trading hands.

An ad to help with our costs